A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The investigational therapy combines mRNA technology with immunotherapy to train the immune system to target cancer cells ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

Health disparities lead to delayed diagnosis of these seven cancer types in the Black community, but awareness and early screening can help save lives.

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

The SunRISe-2 study, in people with muscle-invasive bladder cancer (MIBC) who were not receiving surgery to remove the bladder (cystectomy) and nearby lymph nodes, has been discontinued after it ...

State-of-the-art robotic systems that can help remove tumours or replace a patient’s knee have been approved for use on the ...

Researchers have found that Schistosoma haematobium may increase cervical cancer risk by altering gene activity, even after ...

which raises the risk of the cancer spreading throughout the body. Around 40% of patients don’t respond to BCG, and many go on to have their bladder removed to try to limit the disease.

Teresa Tiano was diagnosed with stomach cancer in 2011. Now she's helping others Canadians with "the orphan cancer." ...